睿知中国医院研究地图
候选清单

广州广州医科大学

广州医科大学附属第一医院

First Affiliated Hospital of Guangzhou Medical University

在本站收录的 61 种疾病中,这家医院列在其中 13 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

广州医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma6 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  3. 肺癌Lung cancer186 篇牵头论文牵头 21 项开放试验
  4. 骨肉瘤Osteosarcoma0 篇牵头论文
  5. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  6. 淋巴瘤Lymphoma1 篇牵头论文
  7. 先天性心脏病Congenital heart disease2 篇牵头论文
  8. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  9. 大动脉炎Takayasu arteritis0 篇牵头论文
  10. 特发性肺纤维化Idiopathic pulmonary fibrosis21 篇牵头论文
  11. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis3 篇牵头论文
  12. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  13. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:肝细胞癌、胃癌、胰腺癌、乳腺癌、胶质瘤、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、冠心病、脊柱侧弯、肝包虫病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 2220242025: 112025

广州有 24 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-03
    发布
    登记号
    NCT06301165

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心东莞、佛山、广州、武汉、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与筛查诱导/同步化疗免疫治疗
论文中的科室耳鼻喉/头颈外科放疗科肿瘤内科
牵头的论文6
  1. Effectiveness and safety of camrelizumab plus apatinib in treating recurrent/metastatic nasopharyngeal carcinoma: a single-arm meta-analysis.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis.2024Molecular biology reports
  3. Dosimetric comparison and evaluation of different convergence modes in nasopharyngeal carcinoma using VMAT treatment deliveries.2024PeerJ免费全文
  4. EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression.2023Cancer immunology research
  5. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.2023Frontiers in immunology免费全文
  6. Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma正在招募NCT06301165研究中心II期2024-03 启动
  2. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  3. Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma状态不明NCT02211677研究中心2014-08 启动
  4. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens状态不明NCT01762514研究中心II期2013-01 启动
PubMed 以外找到的论文(未计入)9
  1. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncology论文
  2. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncology会议摘要
  3. From immune architecture to clinical decision: Insights into the TLS‐based RNA model for metastatic risk in nasopharyngeal carcinoma2025Clinical and Translational Discovery论文
  4. MicroRNA-195-5p suppresses metastasis by targeting VEGFA in nasopharyngeal carcinoma2024Research Square预印本
  5. Data from EBV Infection in Epithelial Malignancies Induces Resistance to Antitumor Natural Killer Cells via F3-Mediated Platelet Aggregation2023未列出期刊其他
  6. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: An open-label phase II study.2023Journal of Clinical Oncology会议摘要
  7. Additional file 2 of Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway2021Figshare数据集
  8. M i R -182-5p I nduced by HIF-1α Promotes Tumorigenesis and Metastasis via Targeting ZFP36L1 in Nasopharyngeal Carcinoma2021Research Square预印本
  9. The Oncogenic Role of HIF-1α/miR-182-5p/ZFP36L1 Signaling Pathway in Nasopharyngeal Carcinoma2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025

广州有 11 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 186 篇,占 0.8%。

牵头论文
186
2021–2025 年
牵头试验
50
任何状态,ClinicalTrials.gov
牵头的开放试验
21
正在或即将招募
作为研究中心的开放试验
32
由其他机构牵头
每年牵头的论文数
2021: 303020212022: 242420222023: 313120232024: 414120242025: 53532025

广州有 17 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 53

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
    分期
    II期
    开始
    2025-06
    发布
    登记号
    NCT06926790

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  2. 正在招募
    Multimodal AI-Guided Recovery Management After Lung Cancer Surgery
    分期
    不分期
    开始
    2025-03
    发布
    登记号
    NCT07588737

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  3. 正在招募
    Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-04
    发布
    登记号
    NCT06383728

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  4. 正在招募
    Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
    分期
    III期
    开始
    2024-03
    发布
    登记号
    NCT06607796

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  5. 正在招募
    A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
    分期
    未注明
    开始
    2024-09
    发布
    登记号
    NCT06718972

    年龄未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  6. 正在招募
    A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
    分期
    II期
    开始
    2024-09
    发布
    登记号
    NCT06775275

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  7. 正在招募
    Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
    分期
    未注明
    开始
    2024-01
    发布
    登记号
    NCT06843707

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  8. 正在招募
    The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
    分期
    不分期
    开始
    2024-07
    发布
    登记号
    NCT06988579

    年龄 40 岁 至 74 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  9. 正在招募
    Early Intervention Strategies for Lung Cancer
    分期
    不分期
    开始
    2024-06
    发布
    登记号
    NCT06988943

    年龄 40 岁 至 74 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  10. 正在招募
    Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
    分期
    I/II期
    开始
    2023-07
    发布
    登记号
    NCT05777278

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  11. 正在招募
    Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
    分期
    不分期
    开始
    2023-09
    发布
    登记号
    NCT06286150

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  12. 正在招募
    LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
    分期
    未注明
    开始
    2019-06
    发布
    登记号
    NCT06778512

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  13. 正在招募
    Non-risk Based Lang Cancer Screening With a One-off LDCT
    分期
    不分期
    开始
    2015-12
    发布
    登记号
    NCT04938804

    年龄 40 岁 至 74 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  14. 即将招募
    Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
    分期
    II期
    开始
    2026-02
    发布
    登记号
    NCT07303881

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  15. 即将招募
    NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
    分期
    I期
    开始
    2026-01
    发布
    登记号
    NCT07318636

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  16. 即将招募
    Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
    分期
    不分期
    开始
    2026-02
    发布
    登记号
    NCT07352176

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  17. 即将招募
    Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
    分期
    不分期
    开始
    2026-03
    发布
    登记号
    NCT07395375

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  18. 即将招募
    Tubeless Strategy for Enhanced Recovery After Sublobar Resection
    分期
    不分期
    开始
    2026-02
    发布
    登记号
    NCT07409129

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  19. 即将招募
    Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
    分期
    II期
    开始
    2026-04
    发布
    登记号
    NCT07413952

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  20. 即将招募
    Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study
    分期
    II期
    开始
    2025-10
    发布
    登记号
    NCT07150416

    年龄 18 岁 至 未注明(登记的条件)

    牵头:广州医科大学附属第一医院广州

  21. 即将招募
    A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
    分期
    不分期
    开始
    2024-06
    发布
    登记号
    NCT06422637

    年龄 40 岁 至 75 岁(登记的条件)

    牵头:广州医科大学附属第一医院广州

  22. 正在招募
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    分期
    I/II期
    开始
    2026-02
    发布
    登记号
    NCT07367529

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、中山、北京、南京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、扬州、杭州、武汉、西安、长沙

  23. 正在招募
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    分期
    III期
    开始
    2026-04
    发布
    登记号
    NCT07416474

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛

  24. 正在招募
    Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
    分期
    II期
    开始
    2026-01
    发布
    登记号
    NCT07492342

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、广州、杭州

  25. 正在招募
    A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
    分期
    III期
    开始
    2026-06
    发布
    登记号
    NCT07554339

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、厦门、台州、合肥、太原、广州、成都、杭州、桂林、武汉、济南、温州、石家庄、福州、重庆、长沙

  26. 正在招募
    A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
    分期
    II/III期
    开始
    2026-10
    发布
    登记号
    NCT07739186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州

  27. 正在招募
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    分期
    III期
    开始
    2025-04
    发布
    登记号
    NCT06875310

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、广州、成都、扬州、新乡、杭州、武汉、汕头、沈阳、济南、深圳、石家庄、福州、苏州、蚌埠、重庆、长春、长沙

  28. 正在招募
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    分期
    III期
    开始
    2025-03
    发布
    登记号
    NCT06890598

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、佛山、北京、南宁、台州、哈尔滨、天津、安阳、广州、成都、杭州、武汉、汕头、洛阳、济南、深圳、苏州、西安、重庆、长沙

  29. 正在招募
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
    分期
    II/III期
    开始
    2025-08
    发布
    登记号
    NCT07005102

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、南昌、广州、成都、武汉、福州

  30. 正在招募
    Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
    分期
    I/II期
    开始
    2025-07
    发布
    登记号
    NCT07079475

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南京、天津、广州、成都、杭州、沈阳、济南、长沙

  31. 正在招募
    A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
    分期
    I/II期
    开始
    2025-09
    发布
    登记号
    NCT07111520

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、南昌、合肥、天津、广州、徐州、成都、扬州、新乡、武汉、济南、石家庄、福州、苏州、襄阳、重庆、长春、青岛

  32. 正在招募
    Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
    分期
    III期
    开始
    2025-08
    发布
    登记号
    NCT07154706

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、南通、天津、广州、成都、杭州、武汉、济南、西安、郑州

  33. 正在招募
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    分期
    III期
    开始
    2025-12
    发布
    登记号
    NCT07182682

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 47 家列出的医院为研究中心上海、北京、南京、南宁、台州、合肥、哈尔滨、天津、太原、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、福州、西安、郑州、长春、长沙

  34. 正在招募
    Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
    分期
    未注明
    开始
    2025-12
    发布
    登记号
    NCT07610616

    年龄 18 岁 至 100 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  35. 正在招募
    PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
    分期
    未注明
    开始
    2025-10
    发布
    登记号
    NCT07775820

    年龄 18 岁 至 未注明(登记的条件)

    牵头:南方医科大学南方医院;另有 4 家列出的医院为研究中心南昌、广州、深圳、温州

  36. 正在招募
    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
    分期
    III期
    开始
    2024-04
    发布
    登记号
    NCT06312137

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南昌、台州、广州、成都、杭州、武汉、济南、福州、苏州、西安、郑州、长春、长沙

  37. 正在招募
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    分期
    III期
    开始
    2024-05
    发布
    登记号
    NCT06345729

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 36 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、无锡、杭州、武汉、济南、温州、福州、苏州、西安、郑州、重庆、长沙

  38. 正在招募
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    分期
    III期
    开始
    2024-06
    发布
    登记号
    NCT06422143

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、乌鲁木齐、北京、南昌、厦门、台州、哈尔滨、广州、成都、扬州、杭州、武汉、温州、福州、郑州、长春、长沙

  39. 正在招募
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    分期
    III期
    开始
    2024-08
    发布
    登记号
    NCT06452277

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 22 家列出的医院为研究中心上海、临沂、北京、南京、厦门、台州、哈尔滨、广州、成都、杭州、武汉、济南、福州、长春、长沙

  40. 正在招募
    A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
    分期
    I期
    开始
    2024-06
    发布
    登记号
    NCT06461156

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  41. 正在招募
    Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
    分期
    II期
    开始
    2024-12
    发布
    登记号
    NCT06497530

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  42. 正在招募
    Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
    分期
    未注明
    开始
    2024-06
    发布
    登记号
    NCT06518655

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、佛山、北京、广州、成都、武汉

  43. 正在招募
    Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
    分期
    未注明
    开始
    2024-06
    发布
    登记号
    NCT06528418

    年龄 18 岁 至 100 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  44. 正在招募
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    分期
    III期
    开始
    2024-10
    发布
    登记号
    NCT06561386

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南宁、南昌、台州、哈尔滨、天津、太原、广州、成都、新乡、杭州、沈阳、济南、福州、重庆、长沙

  45. 正在招募
    A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
    分期
    III期
    开始
    2024-11
    发布
    登记号
    NCT06564324

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、石家庄、苏州、西安、郑州、重庆、长沙

  46. 正在招募
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    分期
    不分期
    开始
    2024-09
    发布
    登记号
    NCT06572540

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、成都、杭州、郑州

  47. 正在招募
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06119581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南昌、台州、哈尔滨、天津、宜昌、常州、广州、成都、杭州、武汉、济南、海口、湛江、福州、襄阳、西安、长沙

  48. 正在招募
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    分期
    III期
    开始
    2023-12
    发布
    登记号
    NCT06170788

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南昌、厦门、台州、合肥、哈尔滨、广州、徐州、成都、无锡、杭州、武汉、济南、湛江、石家庄、福州、襄阳、郑州、长沙

  49. 正在招募
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    分期
    III期
    开始
    2022-03
    发布
    登记号
    NCT04928846

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、临沂、乌鲁木齐、北京、南京、南宁、南昌、南通、厦门、台州、合肥、呼和浩特、哈尔滨、大连、天津、太原、广州、成都、昆明、杭州、武汉、汕头、沈阳、济南、湛江、石家庄、福州、西安、郑州、重庆、长春、长沙

  50. 正在招募
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    分期
    II期
    开始
    2022-09
    发布
    登记号
    NCT05168566

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、临沂、北京、南京、哈尔滨、广州、成都、杭州、武汉、沈阳、蚌埠、郑州、长春、长沙

  51. 正在招募
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    分期
    II/III期
    开始
    2020-12
    发布
    登记号
    NCT04613596

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 30 家列出的医院为研究中心上海、临沂、北京、南宁、南昌、厦门、台州、合肥、哈尔滨、太原、广州、成都、杭州、武汉、沈阳、济南、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙

  52. 正在招募
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    分期
    I/II期
    开始
    2019-07
    发布
    登记号
    NCT04270591

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、济南、石家庄、郑州、长春、长沙

  53. 正在招募
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    分期
    I期
    开始
    2018-04
    发布
    登记号
    NCT03460977

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心南京、广州、成都、温州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科影像/核医学科病理/检验科放疗科
牵头的论文186
  1. Symptom Clusters and Social Support in Patients With Lung Cancer Undergoing Anti-Programmed Death 1/Programmed Death Ligand 1 Immunotherapy: A Cross-sectional Analysis.2026Cancer nursing
  2. Diagnostic performance of 18F-FDG PET/CT metabolic parameters for early prediction of pathological response in NSCLC treated with neoadjuvant immuno(chemo)therapy: A systematic review and meta-analysis.2026European journal of nuclear medicine and molecular imaging
  3. Commentary: Ultrasound Measurements of Skeletal Muscle Predict Chemotherapy Toxicity in Non-Small Cell Lung Cancer.2026Nutrition and cancer
  4. Lactylation of HK2 facilitates cisplatin resistance in NSCLC by promoting cell migration, invasion, and glycolysis.2026Pathology, research and practice
  5. High-dimensional single-cell analysis evaluating effects of different airway management strategies on perioperative immune cells in non-small cell lung cancer surgery.2026Respiratory medicineRCT
  6. Objective Evaluation of Tubeless Thoracic Surgery in Early-Stage Lung Cancer Patients Using Multimodal Digital Device: A Prospective Study.2026The Annals of thoracic surgery
  7. Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer.2026The Annals of thoracic surgery
  8. Nebulized Inhalation of Engineered Extracellular Vesicles to Destruct Pre-metastatic Niche and Inhibit Postoperative Lung Metastasis in a Mouse Model.2025ACS nano
  9. Accuracy of Contrast-enhanced Ultrasonography with Perfluorobutane for Diagnosing Subpleural Lung Lesions.2025Academic radiology
  10. Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer.2025Acta pharmacologica Sinica免费全文
  11. Machine learning and discriminant analysis model for predicting benign and malignant pulmonary nodules.2025BMC medical informatics and decision making免费全文
  12. Cost-effectiveness of risk model-based lung cancer screening in smokers and nonsmokers in China.2025BMC medicine免费全文
  13. Composite dietary antioxidant index and lung cancer risk: insights from the UK biobank.2025BMC public health免费全文
  14. Global lung cancer burden attributable to air fine particulate matter and tobacco smoke exposure: spatiotemporal patterns, sociodemographic characteristics, and transnational inequalities from 1990 to 2021.2025BMC public health免费全文
  15. Conservative management of postoperative incomplete lung torsion without reoperation: first case report with 2-year favorable outcomes.2025BMC surgery免费全文
  16. Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial.2025Cell reports. Medicine免费全文
  17. A novel optimized orthotopic mouse model for brain metastasis with sustained cerebral blood circulation and capability of multiple delivery.2025Clinical & experimental metastasis免费全文
  18. LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study.2025Clinical and translational medicine免费全文
  19. Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.2025Clinical lung cancer
  20. PSMA PET/CT for Improved Staging Accuracy and Imaging of Neovascularization-associated Features in Primary Lung Cancer.2025Clinical nuclear medicine
  21. A-to-I edited SNHG3 promotes non-small cell lung cancer metastasis by promoting fatty acid oxidation and resisting ferroptosis.2025Communications biology免费全文
  22. Prediction and immune infiltration analysis of lipid metabolism-related immune genes in the treatment of non-small cell lung cancer.2025Computers in biology and medicine
  23. Re-thinking the Role of Thoracic Radiotherapy in the First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.2025Current treatment options in oncology
  24. Induction chemoradiotherapy achieves long-term recurrence-free survival in locally advanced pulmonary lymphoepithelioma-like carcinoma: a case report and literature review.2025Frontiers in immunology免费全文
  25. Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study.2025Future oncology (London, England)免费全文
  26. Histomorphological and molecular spectrum of ciliated muconodular papillary tumors with implication for malignant potential: Insights from a literature review and series report.2025Human pathology
  27. Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events.2025Human vaccines & immunotherapeutics免费全文
  28. Mannose Inhibits NSCLC Growth and Inflammatory Microenvironment by Regulating Gut Microbiota and Targeting OGT/hnRNP R/JUN/IL-8 Axis.2025International journal of biological sciences免费全文
  29. Integrating a Multimodal Digital Device for Continuous Perioperative Monitoring in Patients With Lung Cancer Undergoing Thoracic Surgery: Development and Usability Study.2025JMIR mHealth and uHealth免费全文
  30. A Machine Learning Approach to Predicting Mortality Risk in Chemotherapy-Treated Lung Cancer: Machine Learning Model Development and Validation.2025JMIR medical informatics免费全文
  31. Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis.2025Journal for immunotherapy of cancer免费全文
  32. NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC.2025Journal for immunotherapy of cancer免费全文
  33. Advancements in diagnosis and treatment of lung adenocarcinoma patients under ECMO support: a case series and comprehensive literature review.2025Journal of cardiothoracic surgery免费全文
  34. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT免费全文
  35. Comparative Study of Sonazoid and SonoVue Contrast-Enhanced Ultrasound Quantitative Analysis Parameters in Peripheral Lung Cancer Lesions.2025Journal of clinical ultrasound : JCU
  36. circPRMT10 regulated by QKI hypermethylation attenuates lung tumorigenesis induced by tobacco carcinogen NNK.2025Journal of hazardous materials
  37. Dynamic screening initiation using 16 plasma protein biomarkers with polygenic risk and PLCOm2012: a precision prevention framework for lung cancer.2025Journal of translational medicine免费全文
  38. The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.2025Lung cancer (Amsterdam, Netherlands)
  39. Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.2025Lung cancer (Amsterdam, Netherlands)RCT
  40. Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.2025Lung cancer (Amsterdam, Netherlands)
  41. Causal association and potential mediator between lung cancer and tuberculosis: A Mendelian randomization study.2025Microbial pathogenesis
  42. RNF6 Inhibits Lung Adenocarcinoma Cell Proliferation by Promoting Cyclin D2 Degradation.2025Molecular cancer research : MCR
  43. Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients.2025Nature communications免费全文
  44. Comparison of three specimen collection techniques in tissue coagulum clot-based cell block preparation of endobronchial ultrasound-guided transbronchial needle aspiration.2025Pathology, research and practice
  45. The diagnostic performance and optimal strategy of cone beam CT-assisted bronchoscopy for peripheral pulmonary lesions: A systematic review and meta-analysis.2025Pulmonology
  46. CT-based Radiologic Ternary Classification Model in Predicting Pathologic Invasiveness of Pulmonary Nonsolid Nodules.2025Radiology
  47. How I Do It: Management of Pleural-attached Pulmonary Nodules in Low-Dose CT Screening for Lung Cancer.2025Radiology
  48. A rhodamine-coordinated iridium complex to overcome cisplatin-resistant cancer via regulating mitochondrial function triggered apoptosis and ferroptosis.2025Redox biology免费全文
  49. A LncRNA panel within EpCAM-specific exosomes for noninvasive early diagnosing non-small cell lung cancer.2025Respiratory research免费全文
  50. One-step diagnosis of infection and lung cancer using metagenomic sequencing.2025Respiratory research免费全文
  51. Safety and efficacy of a novel transbronchial radiofrequency ablation system for lung tumours: One year follow-up from the first multi-centre large-scale clinical trial (BRONC-RFII).2025Respirology (Carlton, Vic.)免费全文
  52. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.2025Signal transduction and targeted therapy免费全文
  53. Night shift work and lung cancer risk: a prospective cohort study with mediator analysis from the UK Biobank.2025Sleep免费全文
  54. Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-small Cell Lung Cancer.2025The Annals of thoracic surgery
  55. Circular RNA circ_0004470 accelerates the occurrence of lung cancer by promoting DNA damage and cell cycle arrest.2025The Journal of biological chemistry免费全文
  56. Deep learning using histological images for gene mutation prediction in lung cancer: a multicentre retrospective study.2025The Lancet. Oncology
  57. Efficacy and safety of novel airway balloon cryoablation system for malignant central airway obstruction: a prospective, multicentre, randomised, non-inferiority study.2025ThoraxRCT
  58. Diameter thresholds for pure ground-glass pulmonary nodules at low-dose CT screening: Chinese experience.2025Thorax免费全文
  59. Intrapulmonary Epstein-Barr Virus-Associated Smooth Muscle Tumor after Bilateral Lung Transplantation: A Case Report.2025Transplantation proceedings
  60. Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I-III NSCLC.2025Tumori
  61. Application of IdyllaTM System for Rapid Evaluation of EGFR Mutation Status in Formalin-Fixed and Paraffin-Embedded Samples of Non-Small Cell Lung Cancer.2024Annals of clinical and laboratory science
  62. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma.2024Anti-cancer drugs免费全文
  63. Sub-lobar resection versus lobectomy for challenging intraoperative frozen sections in lung adenocarcinoma within 3 cm.2024Asian journal of surgery
  64. Upfront surgery for stage IIIA/B non-small cell lung cancer: retrospective cohort study.2024BJS open免费全文
  65. A clinical analysis and literature review of eleven cases with primary pulmonary angiosarcoma.2024BMC cancer免费全文
  66. Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.2024BMC cancer免费全文
  67. Exhaled VOC detection in lung cancer screening: a comprehensive meta-analysis.2024BMC cancer免费全文
  68. Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report.2024BMC pulmonary medicine免费全文
  69. Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC.2024BMJ open respiratory research免费全文
  70. [18F]FAPI adds value to [18F]FDG PET/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  71. Radiomics signature based on robust features derived from diffusion data for differentiation between benign and malignant solitary pulmonary lesions.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyRCT免费全文
  72. LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.2024Cancer letters
  73. A clinically effective model based on cell-free DNA methylation and low-dose CT for risk stratification of pulmonary nodules.2024Cell reports. Medicine免费全文
  74. EGFR -mutant non-small cell lung cancer patients harboring CDK4 amplification show favorable response to afatinib: Two case reports.2024Chinese medical journal免费全文
  75. Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  76. Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.2024Clinical lung cancer
  77. Impact of smoking cessation duration on lung cancer mortality: A systematic review and meta-analysis.2024Critical reviews in oncology/hematology
  78. Circular RNA circNIPBL regulates TP53-H179R mutations in NNK-induced bronchial epithelial carcinogenesis.2024Environment international
  79. Development of a nomogram for predicting survival in clinical T1N0M1 lung adenocarcinoma: a population-based study.2024European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  80. [64Cu]Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window.2024European journal of nuclear medicine and molecular imaging
  81. The impact of PET/CT and brain MRI for metastasis detection among patients with clinical T1-category lung cancer: Findings from a large-scale cohort study.2024European journal of nuclear medicine and molecular imaging免费全文
  82. Lower respiratory tract microbiome and lung cancer risk prediction in patients with diffuse lung parenchymal lesions.2024Frontiers in cellular and infection microbiology免费全文
  83. Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration.2024Frontiers in immunology免费全文
  84. Proteomics-based Model for Predicting the Risk of Brain Metastasis in Patients with Resected Lung Adenocarcinoma carrying the EGFR Mutation.2024International journal of medical sciences免费全文
  85. Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study.2024International journal of surgery (London, England)免费全文
  86. High-Resolution CT Patterns of Anti-PD1 Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer.2024Journal of computer assisted tomography
  87. Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.2024Journal of experimental & clinical cancer research : CR免费全文
  88. Dual targeting and bioresponsive nano-PROTAC induced precise and effective lung cancer therapy.2024Journal of nanobiotechnology免费全文
  89. Circular RNA hsa_circ_0050386 suppresses non-small cell lung cancer progression via regulating the SRSF3/FN1 axis.2024Journal of translational medicine免费全文
  90. Exploring the molecular and immune-landscape of lung cancer associated with cystic airspaces.2024Molecular immunology
  91. Supervised training models with or without manual lesion delineation outperform clinicians in distinguishing pulmonary cryptococcosis from lung adenocarcinoma on chest CT.2024Mycoses
  92. Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma.2024Neoplasia (New York, N.Y.)免费全文
  93. Solitary pulmonary capillary hemangioma - An underrecognized rare tumor. Report of 32 new cases with literature review.2024Pathology, research and practice
  94. An original aneuploidy-related gene model for predicting lung adenocarcinoma survival and guiding therapy.2024Scientific reports免费全文
  95. The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.2024Signal transduction and targeted therapy免费全文
  96. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.2024The Lancet. Oncology
  97. Solitary Renal Metastases From Stage IA Primary Lung Adenocarcinoma With Co-Alteration of EGFR, RB1, and MAP3K1: A Case Report.2024The clinical respiratory journal免费全文
  98. A Nomogram for Predicting Cancer-Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model.2024The clinical respiratory journal免费全文
  99. Circ0087385 promotes DNA damage in benzo(a)pyrene-induced lung cancer development by upregulating CYP1A1.2024Toxicological sciences : an official journal of the Society of Toxicology
  100. Neoadjuvant immunochemotherapy-a promising strategy for primary pulmonary lymphoepithelioma-like carcinoma.2024World journal of surgical oncology免费全文
  101. The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes.2024World journal of surgical oncology免费全文
  102. Construction and Validation of a Prognostic Model Based on Novel Senescence-Related Genes in Non-Small Cell Lung Cancer Patients with Drug Sensitivity and Tumor Microenvironment.2023Advanced biology
  103. Behind the Indolent Facade: Uncovering the Molecular Features and Malignancy Potential in Lung Minimally Invasive Adenocarcinoma by Single-Cell Transcriptomics.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  104. Characterization of platelet-related genes and constructing signature combined with immune-related genes for predicting outcomes and immunotherapy response in lung squamous cell carcinoma.2023Aging免费全文
  105. Diagnostic performance of diffusion-weighted imaging versus 18F-FDG PET/CT in differentiating pulmonary lesions: an updated meta-analysis of comparative studies.2023BMC medical imaging免费全文
  106. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.2023BMC medicine免费全文
  107. A surgical Decision-making scoring model for spontaneous ventilation- and mechanical ventilation-video-assisted thoracoscopic surgery in non-small-cell lung cancer patients.2023BMC surgery免费全文
  108. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.2023Cancer medicine免费全文
  109. USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl.2023Clinical and translational medicine免费全文
  110. Cellular dynamics in tumour microenvironment along with lung cancer progression underscore spatial and evolutionary heterogeneity of neutrophil.2023Clinical and translational medicine免费全文
  111. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment.2023Clinical and translational medicine免费全文
  112. A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case-Control Study.2023Clinical drug investigation
  113. Sublobar resection reduces the risk of postoperative cognitive dysfunction compared with lobectomy.2023European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery免费全文
  114. Case report: Spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: Exceptional tumor micro-environment.2023Frontiers in immunology免费全文
  115. Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report.2023Human vaccines & immunotherapeutics免费全文
  116. Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients.2023Human vaccines & immunotherapeutics免费全文
  117. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.2023Immunopharmacology and immunotoxicology
  118. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.2023Journal for immunotherapy of cancer免费全文
  119. Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.2023Journal of cancer research and clinical oncology免费全文
  120. The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis.2023Journal of cancer research and clinical oncology免费全文
  121. Risk mapping of lung cancer: a comprehensive appraisal of published meta-analyses incorporating Mendelian randomization studies.2023Journal of cancer research and clinical oncology免费全文
  122. Theranostic applications of selenium nanomedicines against lung cancer.2023Journal of nanobiotechnology免费全文
  123. The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven.2023Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  124. Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test.2023Lung cancer (Amsterdam, Netherlands)
  125. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.2023Lung cancer (Amsterdam, Netherlands)
  126. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.2023Lung cancer (Amsterdam, Netherlands)
  127. Successful chemotherapy with continuous immunotherapy for primary pulmonary endovascular epithelioid hemangioendothelioma: A case report.2023Medicine免费全文
  128. Accurate and Convenient Lung Cancer Diagnosis through Detection of Extracellular Vesicle Membrane Proteins via Förster Resonance Energy Transfer.2023Nano letters免费全文
  129. 5G-Based Remote Virtual Bronchoscopic Navigation-Guided Transbronchial Lung Biopsy for Diagnosis of Lung Cancer: Description of 2 Cases.2023Respiration; international review of thoracic diseases
  130. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study.2023The Lancet. Digital health
  131. The value of folate receptor-positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics.2023The clinical respiratory journal免费全文
  132. Impacts of additional cycles of neoadjuvant immunotherapy on surgery in non-small-cell lung cancer.2023Thoracic cancer免费全文
  133. Current status of diagnosis and treatment of advanced non-small cell lung cancer in China during the COVID-19 pandemic.2022Annals of palliative medicine
  134. Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer.2022Annals of surgery
  135. Nonintubated Robotic-assisted Thoracic Surgery for Tracheal/Airway Resection and Reconstruction: Technique Description and Preliminary Results.2022Annals of surgery免费全文
  136. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.2022Anti-cancer drugs
  137. Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.2022BMC cancer免费全文
  138. Characterization of the fatty acid metabolism-related genes in lung adenocarcinoma to guide clinical therapy.2022BMC pulmonary medicine免费全文
  139. GMFG (glia maturation factor gamma) inhibits lung cancer growth by activating p53 signaling pathway.2022Bioengineered免费全文
  140. Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion.2022Canadian respiratory journal免费全文
  141. Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapy.2022Cancer medicine免费全文
  142. Video-assisted thoracic surgery for ambiguous lung or mediastinal masses in response assessments for hematological malignancies.2022Chinese medical journal免费全文
  143. The CT and PET/CT findings in primary pulmonary lymphoepithelioma-like carcinoma with pathological correlation: a study of 215 cases.2022Clinical radiology
  144. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.2022Critical reviews in oncology/hematology
  145. DNMT3A-mediated high expression of circ_0057504 promotes benzo[a]pyrene-induced DNA damage via the NONO-SFPQ complex in human bronchial epithelial cells.2022Environment international
  146. Predicting EGFR mutation status in lung adenocarcinoma presenting as ground-glass opacity: utilizing radiomics model in clinical translation.2022European radiology
  147. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.2022Frontiers in immunology免费全文
  148. Family Socioeconomic Position and Lung Cancer Risk: A Meta-Analysis and a Mendelian Randomization Study.2022Frontiers in public health免费全文
  149. PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell Lung Cancer.2022International journal of biological sciences免费全文
  150. Spontaneous Ventilation Video-Assisted Thoracoscopic Surgery for Geriatric Patients With Non-Small-Cell Lung Cancer.2022Journal of cardiothoracic and vascular anesthesia
  151. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Predicting and Monitoring the Response of Anti-Angiogenic Treatment in the Orthotopic Nude Mouse Model of Lung Adenocarcinoma.2022Journal of magnetic resonance imaging : JMRI
  152. Serum neurofilament light chain or glial fibrillary acidic protein in the diagnosis and prognosis of brain metastases.2022Journal of neurology
  153. Clinical Utility of F-18 Labeled Fibroblast Activation Protein Inhibitor (FAPI) for Primary Staging in Lung Adenocarcinoma: a Prospective Study.2022Molecular imaging and biology
  154. Hierarchical clock-scale hand-drawn mapping as a simple method for bronchoscopic navigation in peripheral pulmonary nodule.2022Respiratory research免费全文
  155. Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer.2022Respiratory research免费全文
  156. Involvement of m6A regulatory factor IGF2BP1 in malignant transformation of human bronchial epithelial Beas-2B cells induced by tobacco carcinogen NNK.2022Toxicology and applied pharmacology
  157. Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?2021American journal of respiratory and critical care medicine免费全文
  158. Management of nonbacterial thrombotic endocarditis (NBTE) in advanced non-small cell lung cancer (NSCLC) patients with driver mutation: two case reports.2021Annals of palliative medicine
  159. Values of Apparent Diffusion Coefficient and Lesion-to-Spinal Cord Signal Intensity in Diagnosing Solitary Pulmonary Lesions: Turbo Spin-Echo versus Echo-Planar Imaging Diffusion-Weighted Imaging.2021BioMed research international免费全文
  160. CUBIC-plus: An optimized method for rapid tissue clearing and decolorization.2021Biochemical and biophysical research communications
  161. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.2021Cancer
  162. Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.2021Cancer medicine免费全文
  163. Notch1/TAZ axis promotes aerobic glycolysis and immune escape in lung cancer.2021Cell death & disease免费全文
  164. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  165. Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.2021Clinical lung cancer
  166. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis.2021Critical reviews in oncology/hematology
  167. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.2021Critical reviews in oncology/hematology
  168. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.2021Frontiers in immunology免费全文
  169. Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence.2021Frontiers in immunology免费全文
  170. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.2021Frontiers in immunology免费全文
  171. Circ0001320 inhibits lung cancer cell growth and invasion by regulating TNFAIP1 and TPM1 expression through sponging miR-558.2021Human cell
  172. Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.2021Journal of cancer research and clinical oncology免费全文
  173. Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.2021Journal of cancer research and clinical oncology免费全文
  174. DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.2021Lung cancer (Amsterdam, Netherlands)
  175. The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.2021Lung cancer (Amsterdam, Netherlands)免费全文
  176. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis.2021Molecular medicine reports免费全文
  177. Lung cancer risk in patients with multiple sclerosis: a Mendelian randomization analysis.2021Multiple sclerosis and related disorders
  178. Pulmonary artery intimal sarcoma - A primeval or rediscovered tumor? A report of 14 new cases with literature review.2021Pathology, research and practice
  179. Feasibility and Safety of Radiofrequency Ablation Guided by Bronchoscopic Transparenchymal Nodule Access in Canines.2021Respiration; international review of thoracic diseases
  180. Rheumatoid arthritis and risk of lung cancer: Meta-analysis and Mendelian randomization study.2021Seminars in arthritis and rheumatism
  181. The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer.2021Signal transduction and targeted therapy免费全文
  182. Genetically predicted insomnia and lung cancer risk: a Mendelian randomization study.2021Sleep medicine
  183. Family History Associates With Micropapillary Pattern in Lung Adenocarcinoma ≤1.0 cm.2021The Annals of thoracic surgery
  184. Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.2021The Journal of clinical investigation免费全文
  185. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.2021The Lancet. Respiratory medicineRCT
  186. A genome-wide screen for differentially methylated long noncoding RNAs identified that lncAC007255.8 is regulated by promoter DNA methylation in Beas-2B cells malignantly transformed by NNK.2021Toxicology letters
中文论文(未计入)18
  1. [Annual review of interventional pulmonology 2024].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Evaluation of 18F-fibroblast activation protein inhibitor-42 PET/CT in lymphangioleiomyomatosis and its correlation with vascular endothelial growth factor-D].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [An analysis of clinical and genetic feature in pulmonary artery sarcoma].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  4. [Annual therapeutic advances in advanced non-small cell lung cancer in 2024].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  5. [Pulmonary Kaposi sarcoma after lung transplantation: a case report and literature review].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [Molecular Subtype of Small Cell Lung Cancer: 
Challenge for Transforming into Clinical Practice].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  7. [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 
in Mouse Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  8. [Results of Lung Cancer Screening with Low-dose Computed Tomography 
and Exploration of Risk Factors in Guangzhou].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  9. [Cytology Smears of Rapid On-site Evaluation as Supplemental Material 
for Molecular Testing of Non-small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  10. [Brief analysis of diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease].2024Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  11. [Analysis of the efficacy and safety of dual immunotherapy in patients with driver gene and programmed death ligand-1 double negative advanced non-small cell lung cancer].2024Zhonghua yi xue za zhi
  12. [Analysis of Clinicopathological Features on Spread Through Air Spaces
of Lung Adenocarcinoma].2023Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  13. [A case of metastatic breast cancer complicated by pulmonary tumor thrombotic microangiopathy].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  14. [Research Progress on Spread Through Air Spaces of Lung Cancer].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  15. [Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: 
the Progress and Clinical Application].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  16. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].2022Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  17. [Analysis of the Relationship Between the Quality of Small Biopsy Specimens of 
Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene].2021Zhongguo fei ai za zhi = Chinese journal of lung cancer免费全文
  18. [Predictive value of combined detection tumor markers in the diagnosis of lung cancer].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
它在 ClinicalTrials.gov 上的全部试验(任何状态)152
  1. Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases即将招募NCT07413952牵头方II期2026-04 启动
  2. Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection即将招募NCT07395375牵头方不分期2026-03 启动
  3. NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC即将招募NCT07318636牵头方I期2026-01 启动
  4. Tubeless Strategy for Enhanced Recovery After Sublobar Resection即将招募NCT07409129牵头方不分期2026-02 启动
  5. Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer即将招募NCT07303881牵头方II期2026-02 启动
  6. Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)正在招募NCT06926790牵头方II期2025-06 启动
  7. Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study即将招募NCT07150416牵头方II期2025-10 启动
  8. Multimodal AI-Guided Recovery Management After Lung Cancer Surgery正在招募NCT07588737牵头方不分期2025-03 启动
  9. The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening正在招募NCT06988579牵头方不分期2024-07 启动
  10. Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma正在招募NCT06383728牵头方II期2024-04 启动
  11. Early Intervention Strategies for Lung Cancer正在招募NCT06988943牵头方不分期2024-06 启动
  12. A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC正在招募NCT06775275牵头方II期2024-09 启动
  13. Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.正在招募NCT06843707牵头方2024-01 启动
  14. A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy即将招募NCT06422637牵头方不分期2024-06 启动
  15. Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression正在招募NCT05777278牵头方I/II期2023-07 启动
  16. Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery正在招募NCT06286150牵头方不分期2023-09 启动
  17. LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer正在招募NCT06778512牵头方2019-06 启动
  18. Non-risk Based Lang Cancer Screening With a One-off LDCT正在招募NCT04938804牵头方不分期2015-12 启动
  19. Real-Time Non-Invasive Localization for Multiple Lung Nodules已完成NCT07257549牵头方不分期2025-12 启动
  20. Tubeless VATS for Lung Cancer Surgery已完成NCT07057531牵头方不分期2025-07 启动
  21. Robotic-Assisted Navigation for Lung Nodule Localization: A Non-Inferiority Study已完成NCT07055997牵头方不分期2024-06 启动
  22. A Study to Explore the Early Subjective Evaluation and Objective Recovery in Lung Cancer Patients Undergoing Sublobar Resection Versus Lobectomy已完成NCT07288710牵头方2023-03 启动
  23. Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.状态不明NCT05946460牵头方II期2023-08 启动
  24. A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients状态不明NCT06118229牵头方2023-03 启动
  25. Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC状态不明NCT04455594牵头方II期2020-10 启动
  26. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China已完成NCT04830826牵头方2020-07 启动
  27. A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC状态不明NCT03700359牵头方II期2019-03 启动
  28. The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.状态不明NCT04026841牵头方II期2019-07 启动
  29. A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer状态不明NCT04181372牵头方II期2019-12 启动
  30. A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes状态不明NCT03710629牵头方2018-07 启动
  31. A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals状态不明NCT03710616牵头方2018-03 启动
  32. Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion状态不明NCT02011997牵头方III期2013-12 启动
  33. Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC状态不明NCT02140333牵头方III期2013-08 启动
  34. A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer状态不明NCT01872416牵头方II期2012-10 启动
  35. Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung状态不明NCT01872403牵头方II期2012-10 启动
  36. Pain Outcomes Following Video-Assisted Thoracic Surgery (VATS) With LAP Protector状态不明NCT01104233牵头方2010-03 启动
  37. Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer状态不明NCT00923637牵头方II期2009-06 启动
  38. Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors状态不明NCT01105182牵头方2009-11 启动
  39. Video-assisted Thoracoscopic Surgery for Stage IIIA Non-Small Cell Lung Cancer状态不明NCT00862004牵头方II期2008-12 启动
  40. Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer状态不明NCT01054482牵头方II期2007-02 启动
  41. Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer状态不明NCT01051362牵头方II期2006-02 启动
  42. Assisted-VATS Sleeve Lobectomy for Non-small Cell Lung Cancer状态不明NCT00997724牵头方II期1996-02 启动
  43. Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions即将招募NCT07352176牵头方(推断)不分期2026-02 启动
  44. A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China正在招募NCT06718972牵头方(推断)2024-09 启动
  45. Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy正在招募NCT06607796牵头方(推断)III期2024-03 启动
  46. ArticuGrasp Trial: New Flexible Tool vs Standard Grasper for Lung Cancer Node Removal in Keyhole Chest Surgery已完成NCT07201077牵头方(推断)不分期2025-01 启动
  47. Safety and Feasibility of Remote Robotic Bronchoscopy for Peripheral Lung Cancer: A Multicenter, Proof-of-concept Study已完成NCT06613412牵头方(推断)不分期2024-09 启动
  48. A Single-arm Exploratory Study of Neoadjuvant Therapy状态不明NCT05527808牵头方(推断)不分期2022-08 启动
  49. Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC状态不明NCT05001412牵头方(推断)I期2021-01 启动
  50. The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer进行中,不再招募NCT07638878牵头方(推断)2020-11 启动
  51. A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection正在招募NCT07367529研究中心I/II期2026-02 启动
  52. Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC正在招募NCT07492342研究中心II期2026-01 启动
  53. A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)正在招募NCT07739186研究中心II/III期2026-10 启动
  54. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)正在招募NCT07416474研究中心III期2026-04 启动
  55. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)正在招募NCT07554339研究中心III期2026-06 启动
  56. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)正在招募NCT07154706研究中心III期2025-08 启动
  57. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)正在招募NCT06875310研究中心III期2025-04 启动
  58. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery正在招募NCT07182682研究中心III期2025-12 启动
  59. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)正在招募NCT07079475研究中心I/II期2025-07 启动
  60. Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids正在招募NCT07610616研究中心2025-12 启动
  61. A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer正在招募NCT07005102研究中心II/III期2025-08 启动
  62. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer正在招募NCT06890598研究中心III期2025-03 启动
  63. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)正在招募NCT07111520研究中心I/II期2025-09 启动
  64. PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer正在招募NCT07775820研究中心2025-10 启动
  65. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%正在招募NCT06561386研究中心III期2024-10 启动
  66. Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath正在招募NCT06518655研究中心2024-06 启动
  67. A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)正在招募NCT06461156研究中心I期2024-06 启动
  68. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)正在招募NCT06452277研究中心III期2024-08 启动
  69. Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath正在招募NCT06528418研究中心2024-06 启动
  70. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)正在招募NCT06345729研究中心III期2024-05 启动
  71. Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC正在招募NCT06497530研究中心II期2024-12 启动
  72. A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients正在招募NCT06564324研究中心III期2024-11 启动
  73. Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer正在招募NCT06572540研究中心不分期2024-09 启动
  74. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]正在招募NCT06422143研究中心III期2024-06 启动
  75. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)正在招募NCT06312137研究中心III期2024-04 启动
  76. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer正在招募NCT06119581研究中心III期2023-12 启动
  77. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)正在招募NCT06170788研究中心III期2023-12 启动
  78. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)正在招募NCT04928846研究中心III期2022-03 启动
  79. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer正在招募NCT05168566研究中心II期2022-09 启动
  80. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7正在招募NCT04613596研究中心II/III期2020-12 启动
  81. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer正在招募NCT04270591研究中心I/II期2019-07 启动
  82. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma正在招募NCT03460977研究中心I期2018-04 启动
  83. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC进行中,不再招募NCT06883630研究中心I期2025-03 启动
  84. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy已终止NCT06924606研究中心II期2025-07 启动
  85. HTA of NIVATS Based on RWE已完成NCT06574295研究中心2024-08 启动
  86. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer进行中,不再招募NCT06711900研究中心III期2024-10 启动
  87. Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor状态不明NCT06310915研究中心2023-03 启动
  88. Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer状态不明NCT05987345研究中心不分期2023-07 启动
  89. Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer已完成NCT05577702研究中心II期2023-03 启动
  90. To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)状态不明NCT06341660研究中心II期2023-05 启动
  91. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)进行中,不再招募NCT05555732研究中心III期2023-01 启动
  92. A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC进行中,不再招募NCT06443684研究中心2023-05 启动
  93. A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer状态不明NCT06331650研究中心II期2023-08 启动
  94. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC进行中,不再招募NCT05844150研究中心II期2023-06 启动
  95. Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer状态不明NCT05513664研究中心2022-09 启动
  96. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)进行中,不再招募NCT05668988研究中心III期2022-12 启动
  97. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer状态不明NCT05042375研究中心III期2022-09 启动
  98. TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer状态不明NCT05284994研究中心I/II期2022-03 启动
  99. Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer进行中,不再招募NCT05502237研究中心III期2022-10 启动
  100. AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer已终止NCT04993391研究中心I/II期2021-07 启动
  101. Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC已完成NCT04768075研究中心III期2021-05 启动
  102. A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases进行中,不再招募NCT04603807研究中心III期2021-09 启动
  103. Crizotinib Continuation Clinical Study进行中,不再招募NCT05160922研究中心IV期2021-12 启动
  104. Safety and Effectiveness of Radiofrequency Ablation System in the Treatment of Peripheral Lung Tumors已完成NCT04619472研究中心不分期2021-01 启动
  105. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)进行中,不再招募NCT05712902研究中心II期2021-07 启动
  106. A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer已终止NCT04308785研究中心II期2021-12 启动
  107. The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer已完成NCT04206787研究中心2020-05 启动
  108. A Study of Smoking Cessation Patterns in Participants Undergoing Lung Surgery已完成NCT04313361研究中心2020-05 启动
  109. A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers状态不明NCT04462185研究中心2020-07 启动
  110. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)状态不明NCT04234607研究中心III期2020-01 启动
  111. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer进行中,不再招募NCT04194944研究中心III期2020-02 启动
  112. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)已完成NCT04194203研究中心III期2020-04 启动
  113. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer已完成NCT04005716研究中心III期2019-07 启动
  114. A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC状态不明NCT04033354研究中心III期2019-08 启动
  115. Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy状态不明NCT04085250研究中心II期2019-11 启动
  116. A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer已终止NCT03745222研究中心III期2019-05 启动
  117. A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib已完成NCT03535740研究中心II期2019-01 启动
  118. A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer已完成NCT03596866研究中心III期2019-04 启动
  119. A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC状态不明NCT04167774研究中心II期2019-07 启动
  120. Long Term Safety Observation of Crizotinib in Chinese NSCLC Population已终止NCT03672643研究中心IV期2019-01 启动
  121. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)进行中,不再招募NCT03974022研究中心I/II期2019-07 启动
  122. Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)状态不明NCT03972189研究中心II期2019-07 启动
  123. Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR状态不明NCT05767866研究中心I/II期2018-03 启动
  124. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC状态不明NCT03668496研究中心III期2018-11 启动
  125. Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform状态不明NCT03692442研究中心2018-05 启动
  126. Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia状态不明NCT03432637研究中心III期2018-03 启动
  127. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer已终止NCT03516084研究中心III期2018-08 启动
  128. Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer进行中,不再招募NCT03539536研究中心II期2018-10 启动
  129. Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors已终止NCT03272971研究中心不分期2017-12 启动
  130. A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)进行中,不再招募NCT03178552研究中心II/III期2017-09 启动
  131. Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)已完成NCT03059797研究中心II期2017-03 启动
  132. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China已完成NCT03059641研究中心2017-02 启动
  133. NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC状态不明NCT03029273研究中心I期2017-03 启动
  134. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy已完成NCT02813785研究中心III期2016-07 启动
  135. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)已完成NCT02763579研究中心III期2016-06 启动
  136. A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)已完成NCT02657434研究中心III期2016-04 启动
  137. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)已完成NCT02838420研究中心III期2016-08 启动
  138. Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2已完成NCT02867371研究中心不分期2016-08 启动
  139. Plasmodium Immunotherapy for Lung Cancer状态不明NCT02786589研究中心I/II期2016-06 启动
  140. Afatinib in NSCLC With HER2 Mutation已完成NCT02597946研究中心II期2016-03 启动
  141. Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)已完成NCT02388919研究中心II/III期2015-02 启动
  142. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]已完成NCT02486718研究中心III期2015-10 启动
  143. Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation状态不明NCT02448797研究中心III期2015-06 启动
  144. Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma状态不明NCT02103257研究中心IV期2014-03 启动
  145. Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC已完成NCT01945021研究中心II期2013-09 启动
  146. Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy已完成NCT02005458研究中心II期2013-12 启动
  147. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients已完成NCT01639001研究中心III期2012-09 启动
  148. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy已完成NCT01364012研究中心III期2011-05 启动
  149. Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer已完成NCT03117335研究中心III期2011-11 启动
  150. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population已终止NCT01015443研究中心III期2009-12 启动
  151. A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction已完成NCT03448146研究中心III期2009-08 启动
  152. Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer已完成NCT00883675研究中心IV期2009-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 30 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 22 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

淋巴瘤

Lymphoma

2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.03%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

广州有 16 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
    分期
    I期
    开始
    2018-04
    发布
    登记号
    NCT03460977

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心南京、广州、成都、温州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K/AKT/PD-L1 axis.2024International immunopharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma正在招募NCT03460977研究中心I期2018-04 启动
  2. A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma已完成NCT04837222研究中心2021-06 启动
  3. A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)进行中,不再招募NCT05023980研究中心III期2021-09 启动
  4. Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL状态不明NCT02546739研究中心I期2021-03 启动
  5. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib已完成NCT05068440研究中心II期2021-08 启动
  6. A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)状态不明NCT04324879研究中心II期2020-05 启动
  7. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)已完成NCT03797456研究中心II期2019-04 启动
  8. A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib已完成NCT03535740研究中心II期2019-01 启动
  9. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)已完成NCT02838420研究中心III期2016-08 启动
  10. R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma状态不明NCT02428751研究中心III期2015-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.08%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

广州有 12 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies即将招募NCT07858175研究中心2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 6 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Transcatheter Autologous Transfusion to Maintain Pulmonary Circulation During Balloon Pulmonary Angioplasty.2018JACC. Cardiovascular interventions

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 21 篇,占 2.1%。

牵头论文
21
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 7720222023: 5520232024: 4420242025: 332025

广州有 20 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    发布
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙

  2. 正在招募
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    分期
    II期
    开始
    2025-11
    发布
    登记号
    NCT07121413

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科风湿免疫科消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文21
  1. Machine learning-based integration identifies plasma cells-related gene signature ST6GAL1 in idiopathic pulmonary fibrosis.2025BMC pulmonary medicine免费全文
  2. Impaired ciliogenesis in small airway epithelial cells involves in the development of idiopathic pulmonary fibrosis.2025Biochimica et biophysica acta. Molecular basis of disease
  3. Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study.2025Clinical and experimental rheumatology
  4. Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.2024BMC cancer免费全文
  5. Multiomic analysis of monocyte-derived alveolar macrophages in idiopathic pulmonary fibrosis.2024Journal of translational medicine免费全文
  6. Characterizing the lavage and serum cytokine profiles of interstitial pneumonia with autoimmune features and their implications for progressive fibrosis.2024Rheumatology (Oxford, England)免费全文
  7. Overexpression of STX11 alleviates pulmonary fibrosis by inhibiting fibroblast activation via the PI3K/AKT/mTOR pathway.2024Signal transduction and targeted therapy免费全文
  8. Assessing the genetic relationship between gastroesophageal reflux disease and chronic respiratory diseases: a mendelian randomization study.2023BMC pulmonary medicine免费全文
  9. Therapeutic effects of fatty acid binding protein 1 in mice with pulmonary fibrosis by regulating alveolar epithelial regeneration.2023BMJ open respiratory research免费全文
  10. Repairing Mechanisms for Distal Airway Injuries and Related Targeted Therapeutics for Chronic Lung Diseases.2023Cell transplantation免费全文
  11. LncRNA GAS5 suppresses TGF-β1-induced transformation of pulmonary pericytes into myofibroblasts by recruiting KDM5B and promoting H3K4me2/3 demethylation of the PDGFRα/β promoter.2023Molecular medicine (Cambridge, Mass.)免费全文
  12. Mediators of the association between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis.2023The European respiratory journal
  13. Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis.2022Cellular and molecular life sciences : CMLS免费全文
  14. Outcomes after lung transplantation among Chinese patients with connective tissue disease-associated interstitial lung disease and pulmonary hypertension: a retrospective cohort study.2022Clinical and experimental rheumatology
  15. Identification and validation of autophagy-related gene expression for predicting prognosis in patients with idiopathic pulmonary fibrosis.2022Frontiers in immunology免费全文
  16. Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.2022Journal of clinical laboratory analysis免费全文
  17. Effects of bone morphogenetic protein 4 on TGF-β1-induced cell proliferation, apoptosis, activation and differentiation in mouse lung fibroblasts via ERK/p38 MAPK signaling pathway.2022PeerJ免费全文
  18. Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts.2022The European respiratory journal免费全文
  19. Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis.2022The European respiratory journal免费全文
  20. Deleterious Role of Th9 Cells in Pulmonary Fibrosis.2021Cells免费全文
  21. Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.2021Frontiers in immunology免费全文
早期论文(2016–2020 年)5
  1. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.2020BMC pulmonary medicine
  2. Andrographolide ameliorates bleomycin-induced pulmonary fibrosis by suppressing cell proliferation and myofibroblast differentiation of fibroblasts via the TGF-β1-mediated Smad-dependent and -independent pathways.2020Toxicology letters
  3. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.2019Respiration; international review of thoracic diseases
  4. The Role of Follow-up Evaluation in the Diagnostic Algorithm of Idiopathic Interstitial Pneumonia: A Retrospective Study.2019Scientific reports
  5. Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis.2016Stem cell research & therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis正在招募NCT07121413研究中心II期2025-11 启动
  3. A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary Fibrosis即将招募NCT07933133研究中心II期2026-12 启动
  4. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  5. Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06230822研究中心I期2024-03 启动
  6. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  7. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis已终止NCT06360094研究中心II期2024-08 启动
  8. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  9. A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects已完成NCT05895565研究中心I期2023-05 启动
  10. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis已终止NCT06097260研究中心II期2023-11 启动
  11. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  12. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  13. Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND001已完成NCT05657184研究中心I期2021-07 启动
  14. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 3 篇,占 6.7%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

广州有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 6 家医院列在家族性腺瘤性息肉病下全国有 74 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. [Research progress of serrated polyposis syndrome].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

广州医科大学附属第一医院

First Affiliated Hospital of Guangzhou Medical University

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
First affiliated hospital of Guangzhou Medical University

提出更正下载数据